Dietitian-Led Mealtime Insulin Adjustment in Adults With Type 1 Diabetes
Looks back at dietitians adjusting mealtime insulin doses in adults with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: Impact of Dietary Intervention Within an Interprofessional Cooperative Protocol for Prandial Insulin Dose Adjustment in People Living With Type 1 Diabetes
Key facts
- Where
- Paris, FranceSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 69 years old?
Source: NCT07846852, who can take part
Where in France
- Service de diabétologie, Hôpital Lariboisière - AP-HPParis, FranceNo longer taking part
- Service de nutrition - diabétologie, Hôpital Européen Georges Pompidou - AP-HPParis, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT07846852
- Record updated
- 29 September 2026
- Original description
This retrospective multicenter cohort study aims to evaluate the effectiveness of an interprofessional cooperative protocol allowing dietitians to adjust prandial insulin-to-carbohydrate ratios in adults living with type 1 diabetes receiving functional insulin therapy. Glycemic outcomes will be assessed using continuous glucose monitoring data collected during routine clinical care. The primary endpoint is the change in Time in Range (TIR) between baseline and 6 months.Read full original descriptionShow less
Impact of Dietary Intervention Within an Interprofessional Cooperative Protocol for Prandial Insulin Dose Adjustment in People Living With Type 1 Diabetes
This retrospective multicenter cohort study aims to evaluate the effectiveness of an interprofessional cooperative protocol allowing dietitians to adjust prandial insulin-to-carbohydrate ratios in adults living with type 1 diabetes receiving functional insulin therapy. Glycemic outcomes will be assessed using continuous glucose monitoring data collected during routine clinical care. The primary endpoint is the change in Time in Range (TIR) between baseline and 6 months.
Inclusion: Male or female, aged 18 to 69 years; Receiving routine clinical care under an interprofessional cooperation protocol for prandial insulin dose adjustment (protocol implemented since January 1, 2023); Living with type 1 diabetes mellitus or insulin-deficient diabetes, confirmed by the presence of anti-GAD, anti-IA2, anti-ZnT8, or insulin autoantibodies, and requiring optimization of insulin therapy; Diabetes duration greater than 6 months; Treated with multiple daily insulin injections or an insulin pump (open-loop or hybrid closed-loop system); Completion of a structured therapeutic education program in functional insulin therapy (individual consultations and/or educational workshops); Able to understand study information and procedures.
Exclusion: Current treatment with temporary therapies that may affect insulin requirements (e.g., chemotherapy or systemic corticosteroid therapy); Any type of diabetes other than type 1 diabetes or insulin-deficient diabetes; Pregnant women with type 1 diabetes; Unstable severe proliferative diabetic retinopathy; Individuals under legal guardianship, curatorship, or any other legal protection measure; Objection to the use of personal data for research purposes.